Mei Pharma, INC 8-K filings

Lite Strategy, Inc. announced the repurchase of 13% of its outstanding shares since December 2025, funded by treasury operations, thereby increasing the amount of Litecoin held per share.

Lite Strategy, Inc. presented investor materials on July 24, 2026, detailing its strategy to institutionalize Litecoin as a treasury asset, highlighting its first-mover advantage, substantial Litecoin holdings, active treasury management, and a $25M share repurchase program.

Lite Strategy, Inc. announced its fiscal 2026 third quarter results, highlighting $0.7 million in proceeds from its covered call program and the repurchase of 1,629,136 shares.

Lite Strategy, Inc. announced strong fiscal Q2 2026 results, driven by successful Litecoin covered call options generating $600,000 and the launch of a $25 million stock repurchase program.

Lite Strategy, Inc. stockholders approved the 2026 Omnibus Equity Compensation Plan and elected two directors at the annual meeting.

Lite Strategy, Inc. has formalized the employment agreement for Justin J. File, confirming his roles as CEO, CFO, and Secretary with a $575,000 base salary and comprehensive severance package.

Lite Strategy, Inc. announced the appointment of CBIZ CPAs P.C. as its independent registered public accounting firm, replacing Deloitte & Touche LLP, effective December 2, 2025.

Lite Strategy, Inc. filed an 8-K/A to correct the number of stock options granted to CEO Justin J. File and detail a new replacement grant.

Lite Strategy, Inc. has appointed Justin J. File as its permanent Chief Executive Officer and a member of the Board of Directors, effective November 14, 2025.

Lite Strategy, Inc. announced a $25 million common stock repurchase program and a director's resignation, signaling a strategic shift in capital market operations.

An investor in Lite Strategy, Inc. has exercised 1,595,000 pre-funded warrants in a cashless transaction, acquiring 1,594,944 shares of common stock.

MEI Pharma, Inc. has officially changed its name to Lite Strategy, Inc. and its NASDAQ ticker to LITS, signaling a strategic pivot to digital asset treasury management with Litecoin.

MEI Pharma, Inc. has entered into a master loan agreement with BitGo Prime, LLC, establishing a framework for borrowing digital assets or cash secured by collateral.

MEI Pharma, Inc. announced the resignation of Steven D. Wood from its Board of Directors and the immediate appointment of Joshua Riezman, a Managing Director at GSR Strategies, LLC, to the Board.

MEI Pharma announces the acquisition of 929,548 Litecoin tokens, becoming the first U.S.-listed public company to adopt LTC as a primary reserve asset.

MEI Pharma, Inc. announced an investor exercised pre-funded warrants to acquire over 2 million shares of common stock, generating $208.45 in cash.

MEI Pharma, a pharmaceutical company, has announced a $100 million private placement to fund a new strategic direction focused on establishing a Litecoin (LTC) treasury, marking a significant shift and appointing Litecoin founder Charlie Lee to its Board of Directors.

MEI Pharma announced its Q3 fiscal year 2025 results, highlighting a cash position of $20.5 million and the continuation of its strategic alternatives review.

MEI Pharma amends and restates the employment agreement for Acting CEO, CFO, and Secretary Justin J. File, outlining new compensation terms and retention incentives.

MEI Pharma announces its Q2 fiscal year 2025 results, highlighting a cash position of $23.7 million and ongoing evaluation of strategic alternatives.

MEI Pharma held its annual meeting of stockholders on January 30, 2025, and all proposals were approved.

MEI Pharma has announced the date for its 2025 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.

MEI Pharma announced its first quarter fiscal year 2025 results, reporting a cash position of $26.9 million and reaffirming its ongoing evaluation of strategic alternatives.

MEI Pharma has sold its ME-344 program assets to Aardvark Therapeutics for an initial payment of $500,000 plus potential milestone payments of up to $62 million.

MEI Pharma announced its fiscal year 2024 results, highlighting a cash position of $38.3 million and the ongoing evaluation of strategic alternatives.

MEI Pharma is evaluating strategic alternatives, including a potential wind-down, while its CEO and CMO will depart, transitioning into consulting roles to assist with asset liquidation.

MEI Pharma is evaluating strategic options, including a potential wind-down, and will discontinue clinical development of voruciclib while continuing non-clinical activities.

MEI Pharma is evaluating strategic alternatives, including a potential wind-down, and will reduce its workforce and discontinue clinical development of voruciclib.

MEI Pharma has entered into an agreement to terminate its office lease early, resulting in a $3.7 million savings over the lease term and an annual reduction in operating expenses of $2.6 million.

MEI Pharma highlighted clinical data for its drug candidates voruciclib and ME-344, targeting resistance mechanisms in cancer therapies, at the Brookline Virtual MDS and AML Symposium.